Next Article in Journal
Non-Antimicrobial Adjuvant Strategies to Tackle Biofilm-Related Staphylococcus aureus Prosthetic Joint Infections
Next Article in Special Issue
Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Helicobacter Eradication in Korea: An In Vitro Culture-Based Study
Previous Article in Journal
Tylosin Dosage Adjustment Based on Allometric Scaling in Male Turkeys
Previous Article in Special Issue
Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection
Article

Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg)

1
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Donostia/Instituto Biodonostia, Universidad del País Vasco (UPV/EHU), 20014 San Sebastián, Spain
2
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain
3
Department of Surgical and Medical Sciences, University of Bologna, 40138 Bologna, Italy
4
Gastroenterology Unit, Medical Department, Østfold Hospital Trust, 1714 Grålum, Norway
5
Gastroenterology Unit, Athens Medical Paleo Faliron Hospital, 17562 Athens, Greece
6
AM DC Rogaska, 3250 Rogaska Slatina, Slovenia
7
Gastroenterology Unit, Centre Hospitalier Annecy Genvois, 74370 Pringy, France
8
Medicina Interna, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Roma, Italy
9
Gastroenterology Unit, Henry Dunant Hospital, 11526 Athens, Greece
10
Gastroenterology Unit, A.S. Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia
11
Gastroenterology Unit, Department of Clinical Medicine, Trinity College Dublin, D24 NR0A Dublin, Ireland
12
CHU de Charleroi, B-6000 Charleroi, Belgium
13
Althaia Xarxa Assistencial Universitària de Manresa and Universitat de Vic-Universitat Central de Catalunya (UVicUCC), 08242 Manresa, Spain
14
Unit INSERM 1053, Université de Bordeaux, 33076 Bordeaux, France
15
Gastroenterology Unit, Department of Outpatient Therapy and Family Medicine, Tver State Medical University, 170100 Tver, Russia
16
Gastroenterology Unit, Department of Propaedeutic of Internal and Gastroenterology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 127473 Moscow, Russia
*
Author to whom correspondence should be addressed.
These authors contributed equally to this article.
Remaining list of authors, their affiliations, contributions and conflicts of interest are listed in Supplementary file 1. Hp-EuReg Investigators, available online.
Academic Editor: Mitsushige Sugimoto
Antibiotics 2021, 10(9), 1058; https://doi.org/10.3390/antibiotics10091058
Received: 18 July 2021 / Revised: 17 August 2021 / Accepted: 23 August 2021 / Published: 1 September 2021
(This article belongs to the Special Issue Helicobacter pylori: Antibiotic Resistance and Treatment)
Background: Bacterial antibiotic resistance changes over time depending on multiple factors; therefore, it is essential to monitor the susceptibility trends to reduce the resistance impact on the effectiveness of various treatments. Objective: To conduct a time-trend analysis of Helicobacter pylori resistance to antibiotics in Europe. Methods: The international prospective European Registry on Helicobacter pylori Management (Hp-EuReg) collected data on all infected adult patients diagnosed with culture and antimicrobial susceptibility testing positive results that were registered at AEG-REDCap e-CRF until December 2020. Results: Overall, 41,562 patients were included in the Hp-EuReg. Culture and antimicrobial susceptibility testing were performed on gastric biopsies of 3974 (9.5%) patients, of whom 2852 (7%) were naive cases included for analysis. The number of positive cultures decreased by 35% from the period 2013–2016 to 2017–2020. Concerning naïve patients, no antibiotic resistance was found in 48% of the cases. The most frequent resistances were reported against metronidazole (30%), clarithromycin (25%), and levofloxacin (20%), whereas resistances to tetracycline and amoxicillin were below 1%. Dual and triple resistances were found in 13% and 6% of the cases, respectively. A decrease (p < 0.001) in the metronidazole resistance rate was observed between the 2013–2016 (33%) and 2017–2020 (24%) periods. Conclusion: Culture and antimicrobial susceptibility testing for Helicobacter pylori are scarcely performed (<10%) in Europe. In naïve patients, Helicobacter pylori resistance to clarithromycin remained above 15% throughout the period 2013–2020 and resistance to levofloxacin, as well as dual or triple resistances, were high. A progressive decrease in metronidazole resistance was observed. View Full-Text
Keywords: Helicobacter pylori; amoxicillin; clarithromycin; metronidazole; levofloxacin; tetracycline; antibiotic resistance Helicobacter pylori; amoxicillin; clarithromycin; metronidazole; levofloxacin; tetracycline; antibiotic resistance
Show Figures

Figure 1

MDPI and ACS Style

Bujanda, L.; Nyssen, O.P.; Vaira, D.; Saracino, I.M.; Fiorini, G.; Lerang, F.; Georgopoulos, S.; Tepes, B.; Heluwaert, F.; Gasbarrini, A.; Rokkas, T.; Bordin, D.; Smith, S.; Lamy, V.; Caldas, M.; Resina, E.; Muñoz, R.; Cosme, Á.; Puig, I.; Megraud, F.; O’Morain, C.; Gisbert, J.P.; on behalf of the Hp-EuReg Investigators. Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics 2021, 10, 1058. https://doi.org/10.3390/antibiotics10091058

AMA Style

Bujanda L, Nyssen OP, Vaira D, Saracino IM, Fiorini G, Lerang F, Georgopoulos S, Tepes B, Heluwaert F, Gasbarrini A, Rokkas T, Bordin D, Smith S, Lamy V, Caldas M, Resina E, Muñoz R, Cosme Á, Puig I, Megraud F, O’Morain C, Gisbert JP, on behalf of the Hp-EuReg Investigators. Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics. 2021; 10(9):1058. https://doi.org/10.3390/antibiotics10091058

Chicago/Turabian Style

Bujanda, Luis, Olga P. Nyssen, Dino Vaira, Ilaria M. Saracino, Giulia Fiorini, Frode Lerang, Sotirios Georgopoulos, Bojan Tepes, Frederic Heluwaert, Antonio Gasbarrini, Theodore Rokkas, Dmitry Bordin, Sinead Smith, Vincent Lamy, María Caldas, Elena Resina, Raquel Muñoz, Ángel Cosme, Ignasi Puig, Francis Megraud, Colm O’Morain, Javier P. Gisbert, and on behalf of the Hp-EuReg Investigators. 2021. "Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg)" Antibiotics 10, no. 9: 1058. https://doi.org/10.3390/antibiotics10091058

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop